The tumor in one mouse that was injected with human cancer cells completely disappeared.
A new treatment developed by Tel Aviv University could induce the destruction of pancreatic cancer cells, eradicating the number of cancerous cells by up to 90% after two weeks of daily injections of a small molecule known as PJ34.
Pancreatic cancer is one of the hardest cancers to treat. Most people who are diagnosed with the disease do not even live five years after being diagnosed.
pancreatic cancer treatment centers,best pancreatic cancer treatment centers in the world,pancreatic cancer center,pancreatic cancer hospitals,xeloda pancreatic cancer,mesothelin pancreatic cancer,marc lustgarten,pancreas weight loss,liposomal irinotecan pancreatic cancer,irinotecan pancreatic cancer,pancreatic neuroendocrine tumor treatment,advanced pancreatic cancer treatment,metastatic pancreatic cancer treatment,metastatic pancreatic ductal adenocarcinoma,stage 4 metastatic pancreatic cancer,advanced pancreatic cancer prognosis,metastatic pdac,benign pancreatic tumor surgery,pancreatic oncologist near me,metastatic pancreatic cancer,advanced pancreatic cancer,pancreatic cancer metastasis sites,pancreatic cancer specialists,metastatic pancreatic cancer prognosis,late stage pancreatic cancer,pancreatic cancer specialists near me,pancreatic metastasis,metastatic pancreatic adenocarcinoma,pancreatic cancer metastasis to liver,pancreatic cancer liver metastasis,pancreatic cancer doctor,malignant pancreatic cancer,secondary pancreatic cancer,pancreatic oncologist,pancreatic cancer doctors near me,pancreatic cancer bone metastasis,pancreatic cancer metastasis to lung,metastatic pancreatic carcinoma,pancreatic cancer oncologist,metastatic pancreatic neuroendocrine tumor,zantac and pancreatic cancer,advanced stage pancreatic cancer,pancreatic cancer with metastases,memorial sloan kettering pancreatic cancer doctors,pancreatic cancer metastasis to brain,pancreatic cancer spreading to liver,top pancreatic cancer specialists,lynparza pancreatic cancer,pancreatic society,abraxane pancreatic cancer,pancreatobiliary carcinoma,rucaparib pancreatic cancer,kras pancreatic cancer,kras g12d pancreatic cancer,kras g12c pancreatic cancer,kras g12v pancreatic cancer,kras g12r pancreatic cancer,islet cell tumor,pembrolizumab pancreatic cancer,lets win pancreatic cancer,mrcp pancreatic cancer,world pancreatic cancer day 2021,zantac pancreatic cancer,world pancreatic cancer day,pancreatic c,pancreatobiliary adenocarcinoma,pancreatic cancer 2021,cfpac1,pancreatic cancer research foundation,national pancreatic cancer day,pdac pancreatic cancer,adenosquamous carcinoma pancreas,radiotherapy for pancreatic cancer,pancreatic cancer final days,malignant neoplasm of pancreatic duct,pdac oncology,pancreatic cancer mayo,pancreatic cancer heartburn,best pancreatic cancer treatment centers,ozempic pancreatic cancer,best pancreatic cancer doctor,pancreatic adenocarcinoma pathology outlines,best pancreatic cancer doctors in the world,targeted therapy for pancreatic cancer,brca2 and pancreatic cancer,adenocarcinoma pancreas stage 4,stage 4 adenocarcinoma pancreatic cancer,heartburn and pancreatic cancer,lung and pancreatic cancer,ucla pancreatic cancer,pancreatic cancer foundation,american cancer society pancreatic cancer,neuroendocrine pancreatic cancer treatment,pancreatic cancer society,best hospitals for pancreatic surgery,pancreatic cancer support,pancreatic cancer kidneys shutting down,aspc1,i have pancreatic cancer,proton therapy for stage 4 pancreatic cancer
The study, led by Prof. Malka Cohen-Armon and her team at TAU’s Sackler Faculty of Medicine, in collaboration with Dr. Talia Golan’s team at the Cancer Research Center at Sheba Medical Center, was recently published in the journal Oncotarget.
Specifically, the study found that PJ34, when injected intravenously, causes the self-destruction of human cancer cells during mitosis, the scientific term for cell division.
The research was conducted with xenografts, transplantation of human pancreatic cancer into immunocompromised mice. A month after being injected with the molecule daily for 14 days, “there was a reduction of 90% of pancreatic cells in the tumor,” Cohen-Armon told The Jerusalem Post. “In one mouse, the tumor completely disappeared.”
“This molecule causes an anomaly during mitosis of human cancer cells, provoking rapid cell death,” she said. “Thus, cell multiplication itself resulted in cell death in the treated cancer cells.”
Moreover, she said, PJ34 appears to have no impact on healthy cells, thus “no adverse effects were observed.” The mice, she said, continued to grow and gain weight as usual.
She added that she first published about the mechanism in 2017 when it was used to effectively treat triple-negative breast cancer implanted in xenografts. This type of breast cancer – which tests negative for estrogen receptors, progesterone receptors and excess HER2 protein – like pancreatic cancer, is very hard to treat and many women don’t live more than five years after being diagnosed.
The study, led by Prof. Malka Cohen-Armon and her team at TAU’s Sackler Faculty of Medicine, in collaboration with Dr. Talia Golan’s team at the Cancer Research Center at Sheba Medical Center, was recently published in the journal Oncotarget.
Specifically, the study found that PJ34, when injected intravenously, causes the self-destruction of human cancer cells during mitosis, the scientific term for cell division.
The research was conducted with xenografts, transplantation of human pancreatic cancer into immunocompromised mice. A month after being injected with the molecule daily for 14 days, “there was a reduction of 90% of pancreatic cells in the tumor,” Cohen-Armon told The Jerusalem Post. “In one mouse, the tumor completely disappeared.”
“This molecule causes an anomaly during mitosis of human cancer cells, provoking rapid cell death,” she said. “Thus, cell multiplication itself resulted in cell death in the treated cancer cells.”
Moreover, she said, PJ34 appears to have no impact on healthy cells, thus “no adverse effects were observed.” The mice, she said, continued to grow and gain weight as usual.
She added that she first published about the mechanism in 2017 when it was used to effectively treat triple-negative breast cancer implanted in xenografts. This type of breast cancer – which tests negative for estrogen receptors, progesterone receptors and excess HER2 protein – like pancreatic cancer, is very hard to treat and many women don’t live more than five years after being diagnosed.
pancreatic cancer treatment centers,best pancreatic cancer treatment centers in the world,pancreatic cancer center,pancreatic cancer hospitals,xeloda pancreatic cancer,mesothelin pancreatic cancer,marc lustgarten,pancreas weight loss,liposomal irinotecan pancreatic cancer,irinotecan pancreatic cancer,pancreatic neuroendocrine tumor treatment,advanced pancreatic cancer treatment,metastatic pancreatic cancer treatment,metastatic pancreatic ductal adenocarcinoma,stage 4 metastatic pancreatic cancer,advanced pancreatic cancer prognosis,metastatic pdac,benign pancreatic tumor surgery,pancreatic oncologist near me,metastatic pancreatic cancer,advanced pancreatic cancer,pancreatic cancer metastasis sites,pancreatic cancer specialists,metastatic pancreatic cancer prognosis,late stage pancreatic cancer,pancreatic cancer specialists near me,pancreatic metastasis,metastatic pancreatic adenocarcinoma,pancreatic cancer metastasis to liver,pancreatic cancer liver metastasis,pancreatic cancer doctor,malignant pancreatic cancer,secondary pancreatic cancer,pancreatic oncologist,pancreatic cancer doctors near me,pancreatic cancer bone metastasis,pancreatic cancer metastasis to lung,metastatic pancreatic carcinoma,pancreatic cancer oncologist,metastatic pancreatic neuroendocrine tumor,zantac and pancreatic cancer,advanced stage pancreatic cancer,pancreatic cancer with metastases,memorial sloan kettering pancreatic cancer doctors,pancreatic cancer metastasis to brain,pancreatic cancer spreading to liver,top pancreatic cancer specialists,lynparza pancreatic cancer,pancreatic society,abraxane pancreatic cancer,pancreatobiliary carcinoma,rucaparib pancreatic cancer,kras pancreatic cancer,kras g12d pancreatic cancer,kras g12c pancreatic cancer,kras g12v pancreatic cancer,kras g12r pancreatic cancer,islet cell tumor,pembrolizumab pancreatic cancer,lets win pancreatic cancer,mrcp pancreatic cancer,world pancreatic cancer day 2021,zantac pancreatic cancer,world pancreatic cancer day,pancreatic c,pancreatobiliary adenocarcinoma,pancreatic cancer 2021,cfpac1,pancreatic cancer research foundation,national pancreatic cancer day,pdac pancreatic cancer,adenosquamous carcinoma pancreas,radiotherapy for pancreatic cancer,pancreatic cancer final days,malignant neoplasm of pancreatic duct,pdac oncology,pancreatic cancer mayo,pancreatic cancer heartburn,best pancreatic cancer treatment centers,ozempic pancreatic cancer,best pancreatic cancer doctor,pancreatic adenocarcinoma pathology outlines,best pancreatic cancer doctors in the world,targeted therapy for pancreatic cancer,brca2 and pancreatic cancer,adenocarcinoma pancreas stage 4,stage 4 adenocarcinoma pancreatic cancer,heartburn and pancreatic cancer,lung and pancreatic cancer,ucla pancreatic cancer,pancreatic cancer foundation,american cancer society pancreatic cancer,neuroendocrine pancreatic cancer treatment,pancreatic cancer society,best hospitals for pancreatic surgery,pancreatic cancer support,pancreatic cancer kidneys shutting down,aspc1,i have pancreatic cancer,proton therapy for stage 4 pancreatic cancer
Though Cohen-Armon said the team did not specifically study whether or not the treatment could prolong the lifespan of a patient, one can assume such an effect could result if the cancerous cells are eliminated.
How long will it take to move from mice trials to human trials?
She estimates that would take “at least two years on the condition that we get enough funding.”
First, she said, the group will test the treatment on pigs and then apply for permission from the FDA to administer humans with this molecule.
“I am optimistic,” Cohen-Armon concluded.
